TABLE 3

Comparison of ¹⁸F-FDG Uptake and Biomarkers Among Patients with Pulmonary Metastases

	Adenocarcinoma vs. SQC			Adenocarcinoma vs. sarcoma			SQC vs. sarcoma
Biomarker	Adenocarcinoma (n = 103)	SQC (n = 13)	P	Adenocarcinoma(n = 103)	Sarcoma (n = 17)	P	SQC (n = 13)	Sarcoma (n = 17)	P
T/M ratio	3.43 ± 0.27	3.68 ± 0.78	0.7635	3.43 ± 0.27	2.04 ± 0.35	0.0467	3.67 ± 0.78	2.04 ± 0.35	0.0473
Glut1	3.12 ± 0.09	3.39 ± 0.18	0.3012	3.12 ± 0.09	1.82 ± 0.21	<0.0001	3.39 ± 0.18	1.82 ± 0.21	<0.0001
Glut3	1.12 ± 0.04	1.46 ± 0.22	0.0117	1.12 ± 0.04	1.77 ± 0.26	<0.0001	1.46 ± 0.22	1.77 ± 0.26	0.4030
Hexokinase I	2.55 ± 0.09	3.15 ± 0.32	0.0429	2.55 ± 0.09	2.06 ± 0.25	0.6979	3.15 ± 0.32	2.06 ± 0.25	0.0102
HIF-1α	3.02 ± 0.10	3.69 ± 0.17	0.0198	3.02 ± 0.10	1.77 ± 0.24	<0.0001	3.69 ± 0.17	1.77 ± 0.24	<0.0001
VEGF	24.0 ± 1.70	41.5 ± 5.07	0.0009	24.0 ± 1.70	15.7 ± 3.92	0.0482	41.5 ± 5.07	15.7 ± 3.92	0.0003
CD34	24.4 ± 1.14	32.9 ± 2.55	0.0121	24.4 ± 1.14	25.1 ± 2.99	0.8169	32.9 ± 2.55	25.1 ± 2.99	0.0667